Abstract: Radiolabeled compounds of Formula I are described. Processes for radiolabeling the compounds are described. Methods for radioactive imaging using the compounds are also described.

Abstract: The present disclosure is directed to iterative regularized reconstruction methods. In certain embodiments, the methods incorporate locally-weighted total variation denoising to suppress artifacts induced by PSF modeling. In certain embodiments, the methods are useful for suppressing ringing artifacts while contrast recovery is maintained. In certain embodiments, the weighting scheme can be extended to noisy measures introducing a noise-independent weighting scheme. The present disclosure is also directed to a method for quantifying radioligand binding in a subject without collecting arterial blood. In certain embodiments, the methods incorporate using imaging data and electronic health records to predict one or more anchors, which are used to generate an aterial input function (AIF) for the radioligand.

Abstract: The present disclosure is directed to iterative regularized reconstruction methods. In certain embodiments, the methods incorporate locally-weighted total variation denoising to suppress artifacts induced by PSF modeling. In certain embodiments, the methods are useful for suppressing ringing artifacts while contrast recovery is maintained. In certain embodiments, the weighting scheme can be extended to noisy measures introducing a noise-independent weighting scheme. The present disclosure is also directed to a method for quantifying radioligand binding in a subject without collecting arterial blood. In certain embodiments, the methods incorporate using imaging data and electronic health records to predict one or more anchors, which are used to generate an aterial input function (AIF) for the radioligand.

Abstract: The present invention relates to Radiolabeled Compounds labeled with fluorine, bromine, iodine, carbon, or tritium isotopes and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.

Abstract: The present invention relates to Radiolabeled Compounds labeled with fluorine, bromine, iodine, carbon, or tritium isotopes and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.

Abstract: The present invention relates to Radiolabeled Compounds and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.

Abstract: The present invention relates to Radiolabeled Compounds and methods of use thereof for treating or preventing a psychiatric disorder in a subject, for stabilizing the mood of a subject having a mood disorder, or as imaging agents for a serotonin receptor. Compositions comprising an imaging-effective amount of a Radiolabeled Compound are also disclosed.

Abstract: The present invention relates to Radiolabeled Arylsulfonyl Compounds and methods of use thereof as imaging agents for the COX-2 enzyme using positronemission tomograpy (PET). Methods of making the Radiolabeled Arylsulfonyl Compounds and pharmaceutical compositions comprising an effective amount of a Radiolabeled Arylsulfonyl Compound are also disclosed.